Skip to main content

Earth Science Tech, Inc. (ETST) Announces Second Quarter Fiscal 2023 Financial Results, Highlights and Outlook

Miami, FL, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a holding entity set to acquire companies in the health and wellness space currently in compounding pharmaceuticals and telemedicine through its wholly owned subsidiaries, today announced its financial results and operating results for its second quarter fiscal 2023 ended September 30, 2022 as scheduled (view release).

Second Quarter 2023 Highlights:

  • Net loss for the second quarter was $228,360.
  • The Company had a cash balance of $1,205 as of September 30, 2022.
  • The Company had a total asset of $355,762 as of September 30, 2022.
  • Commenced corporate name change to “Smart Curative Solutions, Inc.” and stock ticker change to “SCSI”.

Recent Business Highlights:

  • The Company retired approximately $1,118,334 of its debt, 47% of the Company’s liabilities subsequently from the period ending September 30, 2022, reported 10-Q and will be reflected in the third quarter fiscal 2023 ended period ending December 31, 2022’s 10-Q.

(view filed 8-K)

  • The Company consummated its two merger candidates,, LLC. (“RxCompound”) and Peaks Curative, LLC. (“Peaks”) from its November 7, 2021 executed agreement subsequently amended on November 8, 2022. Both RxCompound and Peaks have approximately 75 days from the date of consummation to complete its PCAOB audit to transition its books and operations into the Company.

(view filed 8-K)

  • The Company is now headquartered at RxCompound, located at 8950 SW 74th Court, Suite 101, Miami, FL 33156. RxCompound relocated to its new larger facility in the month of June 2022 to facilitate its anticipated growth including the in-process addition of a sterile compounding room to offer injectable products.

  • The Company secured funding within the month of October 2022 up to the date the Company achieves cash flow positive status.

(view filed 8-K)

  • RxCompound initiated the buildout of its sterile compounding room within the month of October 2022. It is slated to be operational early in 2023.

  • RxCompound commenced its hazardous compounding room buildout in early November 2022, to increase its product offerings to include hormonal creams. The hazardous compounding room is anticipated to be operational within December 2022.

  • has successfully launched its beta site in the month of July 2022. The ability for additional product offerings are being added prior to its official launch slate for the month of January 2023.

Business Outlook:

  • Complete PCAOB for Peaks within the month of November 2022 and RxCompound early January 2023. Once one or both have been completed, the Company will cease its shell status.

  • The Company to submit application to uplist to OTCQB tier after completion of PCAOB Audit and cessation of “Shell Risk” status.

  • Addition of independent directors to the board.

  • Utilize the Company’s active nonprofit entity, Earth Science Foundation, Inc.

Conference Call and Webcast:

The Company will host a conference call and webcast to discuss its second fiscal quarter results, highlights, and outlook at 5:00 pm Eastern Time. To participate in the telephone conference call please dial in at least 15 minutes prior to start time.

Participant Only Dial-In Information:
Participant Toll-Free:800-267-6316 Primary  
Participant Direct/International:203-518-9783 Alternate  

The conference call will be recorded and can be accessed on the Investor Relations tab on the Company’s website.

About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) a holding entity set to acquire companies in the health and wellness space currently in compounding pharmaceuticals and telemedicine through its wholly owned subsidiaries, LLC. and Peaks Curative, LLC.

To learn more, please visit:

About, LLC., LLC. (“RxCompound”), is a compounding pharmacy that has historically focused on men’s health, specifically medical products directed at ED such as Tadalfil, and Sildenafil Citrate (the generic names for Cialis and Viagra, respectively) and longevity. RxCompound is currently in process on obtaining a sterile compounding room slated to launch January 2023 to provide sterile products for injection.

To learn more please visit:

About Peaks Curative, LLC.

Peaks Curative, LLC. (“Peaks”), is the telemedicine referral site facilitating asynchronous consultations for branded compound medications prepared at RxCompound. Peaks is currently in its final stages on upgrading its website after its soft launch to and increase product offering. Peaks full launch is slated for January 2023.

To learn more please visit:

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:
Nickolas S. Tabraue
CEO & Director

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.